Table 4 CYP2E1, CYP2C19, CYP2D6, mEH and NAT2 genotype frequencies in control subjects and in patients with breast carcinoma.
Genotypes | Controls | All Patients | Â | Â | Premenopausal Patients | Postmenopausal Patients | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Â | n | f | n | f | P | OR (95%CI) | n | f | p | OR (95%CI) | n | f | p | OR (95%CI) |
CYP2E1 (C-1091T) | 244 | Â | 304 | Â | Â | Â | 192 | Â | Â | Â | 111 | Â | Â | Â |
CYP2E1 (C/C) | 232 | 0.95 | 296 | 0.97 | N.S | 1.91(0.72–5.22) | 186 | 0.97 | N.S | 1.6(0.55–4.89) | 109 | 0.98 | N.S | 2.82(0.58–18.57) |
CYP2E1 (C/T) | 12 | 0.05 | 08 | 0.03 | N.S | 0.52(0.19–1.4) | 06 | 0.03 | N.S | 0.62(0.2–1.83) | 02 | 0.02 | N.S | 0.35(0.05–1.71) |
CYP2E1 (T/T) | 00 | 0.00 | 00 | 0.00 | N.S | - | 00 | 0.00 | N.S | - | 00 | 0.00 | N.S | - |
CYP2C19 (exon5 G-A) | 240 | Â | 304 | Â | Â | Â | 193 | Â | Â | Â | 109 | Â | Â | Â |
CYP2C19 (G/G) | 197 | 0.822 | 239 | 0.787 | N.S | 0.8(0.51–1.26) | 155 | 0.804 | N.S | 0.89(0.53–1.49) | 83 | 0.762 | N.S | 0.7(0.39–1.25) |
CYP2C19 (A/G) | 41 | 0.170 | 61 | 0.200 | N.S | 1.22(0.77–1.93) | 37 | 0.191 | N.S | 1.15(0.68–1.94) | 23 | 0.211 | N.S | 1.30(0.71–2.38) |
CYP2C19 (A/A) | 02 | 0.008 | 04 | 0.013 | N.S | 1.59(0.25–12.56) | 01 | 0.005 | N.S | 0.62(0.02–8.76) | 03 | 0.027 | N.S | 3.37(0.45–29.24) |
CYP2D6 (G1934A) | 230 | Â | 300 | Â | Â | Â | 189 | Â | Â | Â | 109 | Â | Â | Â |
CYP2D6 (G/G) | 167 | 0.726 | 235 | 0.783 | N.S | 1.36(0.9–2.07) | 145 | 0.767 | N.S | 1.24(0.78–1.99) | 90 | 0.827 | 0.04 | 1.79(0.97–3.31) |
CYP2D6 (G/A) | 56 | 0.243 | 58 | 0.193 | N.S | 0.74(0.48–1.15) | 41 | 0.217 | N.S | 0.86(0.53–1.42) | 15 | 0.137 | 0.02 | 0.5(0.25–0.96) |
CYP2D6 (A/A) | 07 | 0.031 | 07 | 0.023 | N.S | 0.76(0.24–2.48) | 03 | 0.016 | N.S | 0.51(0.1–2.24) | 04 | 0.036 | N.S | 1.21(0.29–4.74) |
mEH (T348C) | 244 | Â | 306 | Â | Â | Â | 194 | Â | Â | Â | 110 | Â | Â | Â |
mEH1 (Tyr/Tyr) | 113 | 0.463 | 149 | 0.486 | N.S | 1.1(0.77–1.56) | 97 | 0.500 | N.S | 1.16(0.78–1.72) | 52 | 0.472 | N.S | 1.04(0.65–1.67) |
mEH2 (Tyr/His) | 115 | 0.471 | 119 | 0.388 | N.S | 0.71(0.5–1.02) | 70 | 0.360 | 0.02 | 0.63(0.42–0.95) | 47 | 0.427 | N.S | 0.84(0.52–1.35) |
mEH3 (His/His) | 16 | 0.065 | 38 | 0.124 | 0.02 | 2.02(1.06–3.89) | 27 | 0.139 | 0.01 | 2.3(1.15–4.64) | 11 | 0.1 | N.S | 1.58(0.66–3.77) |
NAT2 | 237 | Â | 290 | Â | Â | Â | 184 | Â | Â | Â | 105 | Â | Â | Â |
Rapid Acetylators | 14 | 0.059 | 24 | 0.082 | N.S | 1.44(0.69–3) | 18 | 0.097 | N.S | 1.73(0.79–3.79) | 06 | 0.057 | N.S | 0.97(0.32–2.79) |
Intermediate Acetylators | 105 | 0.443 | 92 | 0.317 | N.S | 0.58(0.4–0.85) | 61 | 0.331 | N.S | 0.62(0.41–0.95) | 30 | 0.285 | 0.006 | 0.52(0.3–0.85) |
Slow Acetylators | 118 | 0.497 | 174 | 0.600 | 0.01 | 1.51(1.05–2.17) | 105 | 0.570 | N.S | 1.34(0.89–2.01) | 69 | 0.657 | 0.006 | 1.93(1.17–3.2) |